Metastatic Colorectal Cancer Epidemiology Forecast

DelveInsight’s ‘Metastatic Colorectal Cancer (mCRC) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Colorectal Cancer (mCRC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Metastatic Colorectal Cancer (mCRC) Understanding

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common.CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.


CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.


Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.


Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.


If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.


Metastatic Colorectal Cancer (mCRC) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Population of Colorectal Cancer, Gender-specific Distribution of Colorectal Cancer, Age-specific Distribution of Colorectal Cancer, Incident Population of Colorectal Cancer based on Tumor Localization, Incident Population of Colorectal Cancer based on CRC Staging and Incident Population of Metastatic Colorectal Cancer (mCRC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.


Metastatic Colorectal Cancer (mCRC) Detailed Epidemiology Segmentation

  • The incident population of CRC in the seven major markets was 518,742 in 2017.
  • The incident population of mCRC in the seven major markets is estimated to be 213,181 in 2020.
  • In the United States, the number of males and females with CRC is estimated to be 89,527 and 63,773, respectively, in 2020.
  • CRC can be divided based upon the tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum. In the United States, the estimated number of CRC cases with tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum was 48,751, 19,616, 46,299, 13,558, and 16,298 cases in 2017 .
  • In 2017, CRC incidence, in the United States, was highest in the age group of 65–84 years, followed by 45–64 years and ≥85 years with 64,184, 54,087, and 16,443 cases, respectively. The lowest incidence of CRC was observed in the people below <20 years (433 cases), preceded by the age group 20–44 years (9,087 cases) in 2017.
  • In the EU5 countries, the incidence of mCRC was maximum in Germany with 23,499 cases, followed by the Italy with 20,310 cases in 2017. While, the least number of cases were in Spain, with 15,400 cases in 2017. 
  • In Japan, the incidence of mCRC is estimated to be 60,482 in 2020.


Scope of the Report

  • The report covers the descriptive overview of Metastatic Colorectal Cancer (mCRC), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Metastatic Colorectal Cancer (mCRC).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Incident Population of Colorectal Cancer, Gender-specific Distribution of Colorectal Cancer, Age-specific Distribution of Colorectal Cancer, Incident Population of Colorectal Cancer based on Tumor Localization, Incident Population of Colorectal Cancer based on CRC Staging and Incident Population of Metastatic Colorectal Cancer (mCRC).


Report Highlights

  • Eleven Year Forecast of Metastatic Colorectal Cancer (mCRC)
  • 7MM Coverage
  • Delvelnsight analysed gender-specific data of mCRC, which suggests that the incidence of mCRC is more frequent in males than in females.
  • Delvelnsight has also analysed data on types of CRC based on CRC staging, which suggests that localized CRC was the most common type of CRC, followed by regional type.
  • CRC can also be divided based upon the tumor localization at the right colon, transverse, left colon, rectosigmoid, and rectum. As per Delvelnsight’s analysis, the maximum number of incident cases of CRC are found at the right colon followed by the left colon.
  • Age-specific data of CRC suggests that incidence of CRC in the US, was highest in the age group of 65–84 years, followed by 45–64 years and ≥85 years.


Key Questions Answered

  • What is the disease risk, burden and unmet needs of Metastatic Colorectal Cancer (mCRC)?
  • What is the historical Metastatic Colorectal Cancer (mCRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Metastatic Colorectal Cancer (mCRC) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Metastatic Colorectal Cancer (mCRC)?
  • Out of the above-mentioned countries, which country would have the highest incident population of Metastatic Colorectal Cancer (mCRC)during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Colorectal Cancer (mCRC).
  • To understand the future market competition in the Metastatic Colorectal Cancer (mCRC) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) market.
  • To understand the future market competition in the Metastatic Colorectal Cancer (mCRC)market.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

1 KEY INSIGHTS

2 EXECUTIVE SUMMARY

3 METASTATIC COLORECTAL CANCER (MCRC) OVERVIEW AT A GLANCE

4 DISEASE BACKGROUND AND OVERVIEW: METASTATIC COLORECTAL CANCER (MCRC)

4.1 INTRODUCTION

4.2 CAUSES

4.3 SYMPTOMS

4.4 CRC STAGING

4.5 RISK FACTORS OF CRC

4.6 MOLECULAR SUBTYPES OF CRC

4.7 MECHANISMS OF METASTASIS IN CRC

4.8 DRUG RESISTANCE IN MCRC

4.9 CLINICAL PRESENTATION OF MCRC

4.10 UNUSUAL SITES OF METASTASIS IN CRC

4.10.1 Uterine Metastasis

4.10.2 Penile Metastasis

4.10.3 Scrotal Metastasis

4.10.4 Prostatic Metastasis

4.10.5 Bladder Metastasis

4.10.6 Peritoneal Pseudomyxoma

4.10.7 Abdominal Wall Metastasis

4.10.8 Bone Metastasis

4.10.9 Carcinomatous Lymphangitis

4.10.10 Adenopathies

4.10.11 Pancreatic Metastasis

4.11 BIOMARKERS IN MCRC

4.11.1 Prognostic Biomarkers

4.11.2 Patient-Related Factors

4.11.3 Tumor-related Factors

4.11.4 Predictive Biomarkers

4.11.5 Markers to Predict 5-FU Response and Toxicity

4.11.6 Predicting Response to EGFR Therapy

4.11.7 Predicting Response to VEGF Inhibitors

4.11.8 Technology-Facilitated Biomarkers

4.12 DIAGNOSIS

4.12.1 Clinical symptoms

4.12.2 Endoscopy

4.12.3 Imaging

4.12.4 Laboratory

4.12.5 Pathology

4.12.6 Biopsy

4.12.7 Molecular Testing of the Tumor

4.12.8 Blood Tests

4.12.9 Tumor-based Tests

4.12.10 Diagnosis of colorectal liver metastasis

5 RECOGNIZED ESTABLISHMENTS

6 EPIDEMIOLOGY AND PATIENT POPULATION

6.1 KEY FINDINGS

6.2 7MM INCIDENT POPULATION OF COLORECTAL CANCER

6.3 7MM INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER

7 7MM EPIDEMIOLOGY OF METASTATIC COLORECTAL CANCER

7.1 ASSUMPTIONS AND RATIONALE

7.2 UNITED STATES

7.2.1 Incident Cases of Colorectal Cancer in the United States

7.2.2 Gender-specific Distribution of Colorectal Cancer in the United States

7.2.3 Age-specific Distribution of Colorectal Cancer in the United States

7.2.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United States

7.2.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United States

7.2.7 Incident Cases of Metastatic Colorectal Cancer in the United States

7.3 EU5 COUNTRIES

7.4 GERMANY

7.4.1 Incident Cases of Colorectal Cancer in Germany

7.4.2 Gender-specific Distribution of Colorectal Cancer in Germany

7.4.3 Age-specific Distribution of Colorectal Cancer in Germany

7.4.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Germany

7.4.6 Incident Cases of Colorectal Cancer based on CRC Staging in Germany

7.4.7 Incident Cases of Metastatic Colorectal Cancer in Germany

7.5 FRANCE

7.5.1 Incident Cases of Colorectal Cancer in France

7.5.2 Gender-specific Distribution of Colorectal Cancer in France

7.5.3 Age-specific Distribution of Colorectal Cancer in France

7.5.5 Incident Cases of Colorectal Cancer based on Tumor Localization in France

7.5.6 Incident Cases of Colorectal Cancer based on CRC Staging in France

7.5.7 Incident Cases of Metastatic Colorectal Cancer in France

7.6 ITALY

7.6.1 Incident Cases of Colorectal Cancer in Italy

7.6.2 Gender-specific Distribution of Colorectal Cancer in Italy

7.6.3 Age-specific Distribution of Colorectal Cancer in Italy

7.6.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Italy

7.6.6 Incident Cases of Colorectal Cancer based on CRC Staging in Italy

7.6.7 Incident Cases of Metastatic Colorectal Cancer in Italy

7.7 SPAIN

7.7.1 Incident Cases of Colorectal Cancer in Spain

7.7.2 Gender-specific Distribution of Colorectal Cancer in Spain

7.7.3 Age-specific Distribution of Colorectal Cancer in Spain

7.7.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Spain

7.7.6 Incident Cases of Colorectal Cancer based on CRC Staging in Spain

7.7.7 Incident Cases of Metastatic Colorectal Cancer in Spain

7.8 UNITED KINGDOM

7.8.1 Incident Cases of Colorectal Cancer in the United Kingdom

7.8.2 Gender-specific Distribution of Colorectal Cancer in the United Kingdom

7.8.3 Age-specific Distribution of Colorectal Cancer in the United Kingdom

7.8.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United Kingdom

7.8.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United Kingdom

7.8.7 Incident Cases of Metastatic Colorectal Cancer in the United Kingdom

7.9 JAPAN

7.9.1 Incident Cases of Colorectal Cancer in Japan

7.9.2 Gender-specific Distribution of Colorectal Cancer in Japan

7.9.3 Age-specific Distribution of Colorectal Cancer in Japan

7.9.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Japan

7.9.6 Incident Cases of Colorectal Cancer based on CRC Staging in Japan

7.9.7 Incident Cases of Metastatic Colorectal Cancer in Japan

8 APPENDIX

8.1 BIBLIOGRAPHY

8.2 REPORT METHODOLOGY

9 DELVEINSIGHT CAPABILITIES

10 DISCLAIMER

11 ABOUT DELVEINSIGHT

List of Table

TABLE 1: SUMMARY OF MCRC, MARKET, EPIDEMIOLOGY AND KEY EVENTS (2017-2030)

TABLE 2: AJCC STAGING FOR CRC

TABLE 3: PROGNOSTIC FACTORS IN MCRC

TABLE 4: PREDICTIVE FACTORS FOR TARGETED THERAPIES IN MCRC.

TABLE 5: THE LIST OF BIOMARKERS USED IN THE CLINICAL PRACTICE OF MCRC

TABLE 6: RECOGNIZED ESTABLISHMENTS

TABLE 7: PERCENTAGE OF PATIENTS THAT ARE PRESCRIBED DIFFERENT LINES OF TREATMENT FOR MCRC

TABLE 8: RECOMMENDATIONS ON SYMPTOM MANAGEMENT

TABLE 9: RECOMMENDATIONS ON DIAGNOSIS

TABLE 10: RECOMMENDATIONS ON STAGING

TABLE 11: FIRST-LINE TREATMENT

TABLE 12: RECOMMENDATIONS ON SECOND-LINE SYSTEMIC COLORECTAL METASTATIC TREATMENT

TABLE 13: RECOMMENDATIONS ON THIRD-LINE AND FOURTH-LINE SYSTEMIC COLORECTAL METASTATIC TREATMENT

TABLE 14: RECOMMENDATIONS ON LIVER-DIRECTED THERAPIES IN PATIENTS WITH MCRC

TABLE 15: SUMMARY TREATMENT OPTIONS FOR LATE-STAGE CRC

TABLE 16: RECOMMENDATIONS ON SURVEILLANCE/FOLLOW-UP

TABLE 17: MCRC: SIGN RECOMMENDATIONS

TABLE 18: MCRC TREATMENT: GRADE RECOMMENDATIONS

TABLE 19: EVALUATION OF ELDERLY PATIENTS: SIGN RECOMMENDATIONS

TABLE 20: SURGERY: SIGN RECOMMENDATIONS

TABLE 21: LIVER-DIRECTED THERAPIES: SIGN RECOMMENDATIONS

TABLE 22: NON-LIVER-DIRECTED THERAPIES: SIGN RECOMMENDATIONS

TABLE 23: RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF MCRC

TABLE 24: INCIDENT POPULATION OF COLORECTAL CANCER IN THE 7MM (2017-2030)

TABLE 25: INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER IN THE 7MM (2017-2030)

TABLE 26: INCIDENCE OF COLORECTAL CANCER IN THE US (2017-2030)

TABLE 27: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017-2030)

TABLE 28: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017-2030)

TABLE 29: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE US (2017-2030)

TABLE 30: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE US (2017-2030)

TABLE 31: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE US (2017-2030)

TABLE 32: INCIDENT CASES OF COLORECTAL CANCER IN GERMANY (2017-2030)

TABLE 33: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017-2030)

TABLE 34: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017-2030)

TABLE 35: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN GERMANY (2017-2030)

TABLE 36: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN GERMANY (2017-2030)

TABLE 37: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN GERMANY (2017-2030)

TABLE 38: INCIDENT CASES OF COLORECTAL CANCER IN FRANCE (2017-2030)

TABLE 39: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017-2030)

TABLE 40: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017-2030)

TABLE 41: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN FRANCE (2017-2030)

TABLE 42: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN FRANCE (2017-2030)

TABLE 43: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN FRANCE (2017-2030)

TABLE 44: INCIDENT CASES OF COLORECTAL CANCER IN ITALY (2017-2030)

TABLE 45: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017-2030)

TABLE 46: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017-2030)

TABLE 47: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN ITALY (2017-2030)

TABLE 48: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN ITALY (2017-2030)

TABLE 49: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN ITALY (2017-2030)

TABLE 50: INCIDENT CASES OF COLORECTAL CANCER IN SPAIN (2017-2030)

TABLE 51: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017-2030)

TABLE 52: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017-2030)

TABLE 53: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN SPAIN (2017-2030)

TABLE 54: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN SPAIN (2017-2030)

TABLE 55: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN SPAIN (2017-2030)

TABLE 56: INCIDENT CASES OF COLORECTAL CANCER IN THE UK (2017-2030)

TABLE 57: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017-2030)

TABLE 58: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017-2030)

TABLE 59: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE UK (2017-2030)

TABLE 60: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE UK (2017-2030)

TABLE 61: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE UK (2017-2030)

TABLE 62: INCIDENT CASES OF COLORECTAL CANCER IN JAPAN (2017-2030)

TABLE 63: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017-2030)

TABLE 64: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017-2030)

TABLE 65: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN JAPAN (2017-2030)

TABLE 66: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN JAPAN (2017-2030)

TABLE 67: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN JAPAN (2017-2030)

List of Figures

FIGURE 1: MECHANISMS OF METASTASIS IN CRC- HEMATOGENOUS VERSUS PERITONEAL SPREAD.

FIGURE 2: CURRENT AND EMERGING BIOMARKERS USED IN PERSONALIZING TREATMENT FOR PATIENTS WITH MCRC

FIGURE 3: EGFR SIGNALING PATHWAY WITH POTENTIAL PREDICTIVE MARKERS

FIGURE 4: VEGF SIGNALING PATHWAY

FIGURE 5: NCCN GUIDELINES FOR COLON CANCER

FIGURE 6: NCCN GUIDELINES FOR THE TREATMENT OF RECTAL CANCER

FIGURE 7: ZURICH TREATMENT ALGORITHM

FIGURE 8: INCIDENT POPULATION OF COLORECTAL CANCER IN THE 7MM (2017–2030)

FIGURE 9: INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER IN THE 7MM (2017–2030)

FIGURE 10: INCIDENT CASES OF COLORECTAL CANCER IN THE US (2017–2030)

FIGURE 11: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017–2030)

FIGURE 12: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017–2030)

FIGURE 13: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE US (2017–2030)

FIGURE 14: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE US (2017–2030)

FIGURE 15: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE US (2017–2030)

FIGURE 16: INCIDENT CASES OF COLORECTAL CANCER IN GERMANY (2017–2030)

FIGURE 17: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017–2030)

FIGURE 18: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017–2030)

FIGURE 19: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN GERMANY (2017–2030)

FIGURE 20: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN GERMANY (2017–2030)

FIGURE 21: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN GERMANY (2017–2030)

FIGURE 22: INCIDENT CASES OF COLORECTAL CANCER IN FRANCE (2017–2030)

FIGURE 23: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017–2030)

FIGURE 24: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017–2030)

FIGURE 25: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN FRANCE (2017–2030)

FIGURE 26: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN FRANCE (2017–2030)

FIGURE 27: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN FRANCE (2017–2030)

FIGURE 28: INCIDENT CASES OF COLORECTAL CANCER IN ITALY (2017–2030)

FIGURE 29: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017–2030)

FIGURE 30: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017–2030)

FIGURE 31: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN ITALY (2017–2030)

FIGURE 32: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN ITALY (2017–2030)

FIGURE 33: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN ITALY (2017–2030)

FIGURE 34: INCIDENT CASES OF COLORECTAL CANCER IN SPAIN (2017–2030)

FIGURE 35: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017–2030)

FIGURE 36: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017–2030)

FIGURE 37: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN SPAIN (2017–2030)

FIGURE 38: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN SPAIN (2017–2030)

FIGURE 39: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN SPAIN (2017–2030)

FIGURE 40: INCIDENT CASES OF COLORECTAL CANCER IN THE UK (2017–2030)

FIGURE 41: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017–2030)

FIGURE 42: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017–2030)

FIGURE 43: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE UK (2017–2030)

FIGURE 44: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE UK (2017–2030)

FIGURE 45: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE UK (2017–2030)

FIGURE 46: INCIDENT CASES OF COLORECTAL CANCER IN JAPAN (2017–2030)

FIGURE 47: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017–2030)

FIGURE 48: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017–2030)

FIGURE 49: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN JAPAN (2017–2030)

FIGURE 50: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN JAPAN (2017–2030)

FIGURE 51: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN JAPAN (2017–2030)

  • Tags:
  • Metastatic Colorectal Cancer Epidem...
  • Metastatic Colorectal Cancer
  • Metastatic Colorectal Cancer Pipel...
  • Metastatic Colorectal Cancer Compa...
  • Metastatic Colorectal Cancer preva...
  • Metastatic Colorectal Cancer incid...
  • Metastatic Colorectal Cancer patie...
  • Metastatic Colorectal Cancer treat...

Forward to Friend

Need A Quote